Wellington Shields Capital Management LLC Sells 6,473 Shares of Pfizer Inc. $PFE

Wellington Shields Capital Management LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 30.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,955 shares of the biopharmaceutical company’s stock after selling 6,473 shares during the period. Wellington Shields Capital Management LLC’s holdings in Pfizer were worth $363,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PFE. Machina Capital S.A.S. lifted its position in Pfizer by 308.1% during the second quarter. Machina Capital S.A.S. now owns 245,222 shares of the biopharmaceutical company’s stock valued at $5,944,000 after buying an additional 185,134 shares during the period. Westside Investment Management Inc. increased its stake in shares of Pfizer by 7.3% in the 2nd quarter. Westside Investment Management Inc. now owns 17,714 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 1,205 shares in the last quarter. Texas Bank & Trust Co lifted its position in Pfizer by 4.1% during the 2nd quarter. Texas Bank & Trust Co now owns 36,304 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 1,440 shares during the period. Snider Financial Group boosted its stake in Pfizer by 6.5% during the second quarter. Snider Financial Group now owns 12,170 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 745 shares in the last quarter. Finally, Torray Investment Partners LLC grew its holdings in Pfizer by 388.9% in the second quarter. Torray Investment Partners LLC now owns 650,890 shares of the biopharmaceutical company’s stock worth $15,778,000 after purchasing an additional 517,746 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $24.68 on Monday. The stock has a market capitalization of $140.29 billion, a price-to-earnings ratio of 13.13, a PEG ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.64. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business’s fifty day moving average price is $24.77 and its 200-day moving average price is $24.30.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.24.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.